In short
This article discusses the use of Flucloxacillin Sodium Monohydrate in clinical trials for treating complicated Staphylococcus aureus bacteremia (SAB). The focus is on a study called the SAFE-trial, which aims to determine if a shorter antibiotic treatment duration can be as effective as the standard longer treatment for patients with complicated SAB. This research is important for potentially improving patient care and reducing antibiotic use.
At a glance
- Study Name
- SAFE-trial (Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia)
- Main Objective
- To determine if 4 weeks of antibiotic treatment is non-inferior to 6 weeks in patients with complicated SAB
- Drug Used
- Flucloxacillin Sodium Monohydrate (250mg Powder for Solution for Injection or Infusion)
- Administration Route
- Intravenous
- Maximum Daily Dose
- 12,000 mg
- Maximum Treatment Period
- 6 weeks
- Primary Outcome
- Success of therapy at 180 days after randomization
- Key Inclusion Criteria
- Adults with methicillin-sensitive complicated SAB, evidence of organ involvement or deep-seated infection
- Key Exclusion Criteria
- Infected prosthetic material not removed within 14 days, undrained large abscesses, pregnancy or lactation
What is Flucloxacillin Sodium Monohydrate?
Flucloxacillin Sodium Monohydrate is an antibiotic medication used to treat various bacterial infections. It belongs to a class of antibiotics called penicillins, which work by killing bacteria or preventing their growth. This medication is also known by its brand name "Flucloxacillin 250mg Powder for Solution for Injection or Infusion".
Medical Uses
Flucloxacillin is primarily used to treat infections caused by a type of bacteria called Staphylococcus aureus. One of the most serious conditions it treats is Staphylococcus aureus bacteremia (SAB), which is when these bacteria enter the bloodstream. This condition can be life-threatening and requires prompt treatment.
Administration
Flucloxacillin Sodium Monohydrate is administered intravenously, which means it's given directly into a vein. This method allows the medication to enter your bloodstream quickly and start fighting the infection immediately.
Dosage
The dosage of Flucloxacillin can vary depending on the severity of the infection and other factors. However, the maximum daily dose is typically 12,000 mg (12 grams). The duration of treatment can last up to 6 weeks, but this may change based on how well you respond to the medication.
Current Clinical Trial
A clinical trial called the "SAFE-trial" is currently being conducted to study the use of Flucloxacillin in treating complicated Staphylococcus aureus bacteremia. The main objective of this trial is to determine if a shorter treatment duration (4 weeks) is as effective as the standard 6-week treatment for patients who have responded well to initial therapy.
Eligibility Criteria for the Clinical Trial
To participate in this clinical trial, patients must meet certain criteria:
- Be an adult with methicillin-sensitive complicated SAB
- Have evidence of organ involvement or deep-seated infection (such as endocarditis, an infection of the heart valves, or spondylodiscitis, an infection of the spine)
- Have certain risk factors for complicated SAB, such as community-acquired infection or delayed treatment
- Show a satisfactory response to initial treatment, including negative blood cultures and reduction in inflammation markers
Exclusion Criteria for the Clinical Trial
Certain conditions may prevent participation in the trial:
- Presence of infected prosthetic heart valves or other infected prosthetic materials that are not removed within 14 days of antibiotic therapy
- Presence of large undrained abscesses (5 cm or more) after 14 days of antibiotic treatment
- Pregnancy or breastfeeding
Primary Outcome of the Clinical Trial
The main goal of the trial is to assess the success of therapy 180 days after randomization. Success is defined as:
- Patient survival
- No evidence of infection relapse, meaning no recurrence of symptoms or signs of infection with S. aureus found in blood or other normally sterile sites
This trial aims to potentially reduce the duration of antibiotic treatment for complicated SAB, which could lead to fewer side effects and improved quality of life for patients.